Pharmacyclics, Inc. PCYC announced today that the international, randomized Phase III clinical
trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and
rituximab in patients with relapsed or refractory chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL) has enrolled its fifth patient.
The enrollment of the fifth patient has subsequently triggered a third $50
million milestone payment obligation from Janssen Biotech, Inc., one of the
Janssen Pharmaceutical Companies, worldwide collaborator on ibrutinib in
oncology and sponsor of this CLL3001 trial.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in